For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and Attruby represents a genuine breakthrough . These groundbreaking therapies stabilize the transthyretin protein, slowing its destructive build-up and reducing the burden of the condition . Patients are now reporti